Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program

Conditions

Metastatic Castration Resistant Prostate Cancer Patients

Brief summary

Toward personalised treatment in early metastatic prostate cancer based on the assessment of biomarkers in cancer tissue samples and circulating tumour cells.

Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C, Farace F.

2016-02-2968 citations

10.1186/s12885-016-2192-6

Molecular characterization of heterogeneity in circulating tumor cells (CTCs) and tumor samples of metastatic castration-resistant prostate cancer (mCRPC) patients: The multicenter PETRUS program.

Christophe Massard, Marianne Oulhen, Sylvestre Le Moulec, Yohann Loriot, Nathalie Auger et al. (13 authors)

Journal of Clinical Oncology2015-03-01

10.1200/jco.2015.33.7_suppl.165

Interventions

OTHERmetastasis biopsy

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Prostate Cancer patients * Castration Resistant * Prostatic tissue available * Metastasis which may be biopsied

Design outcomes

Primary

Measure	Time frame	Description
Biomarker	assessed at the end of recruitment, up to 2 years	success to evaluate at least one molecular analysis in tumor tissues (prostate and/or metastatic site) AND in CTC

Countries

France

Outcome results

None listed